Cohort Company News

Bigfoot Scores FDA Clearance for Diabetes Management System

Bigfoot Biomedical is a company that MD+DI readers should be quite familiar with by now. In 2017, the diabetes company was selected as the readers' choice for Medtech Company of the Year. The company is developing products to optimize insulin dosing and provide automated insulin delivery for people with insulin-requiring diabetes.
Read More →

Singapore creates Magnesium-based bioresorbable implant technology for surgeries, featuring Magloy Tech

SRS Life Sciences, a global company headquartered in Singapore focused on lessening disease burden across emerging nations, and Magloy Tech, a spin-off from the National University of Singapore’s Graduate Research Innovation Programme (GRIP), have joined forces to internationally further develop and commercialise bioresorbable magnesium implants for orthopaedics and trauma surgery.
Read More →

Sentien Biotechnologies Completes Enrollment of First Cohort in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced it has completed enrollment of the first cohort in its Phase 1/2 study of SBI-101 for the treatment of severe COVID-19. SBI-101, Sentien’s innovative cell-based therapy, is being evaluated in COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT).
Read More →